COMP <GO>
AMGN vs JNJ // PIOTROSKI F-SCORE QUALITY
Amgen Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AMGN 5
— JNJ 9
■ METRIC PARITY
LAST: $466.01 (+1.15%) • MKT CAP: $249.09B
piotroski-score
8/9
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMGN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMGN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.20% | 67.90% | -0.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.50% | 25.50% | -11.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.2x | 18.5x | +8.70 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.25% | 2.97% | +0.28 | AMGN | /fcf-yield <GO> |
| Operating Margin | 24.70% | 34.70% | -10.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 21.00% | 28.50% | -7.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 10.00% | 6.00% | +4.00 | AMGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.06% | 0.00% | +2.06 | AMGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 5.59 | -1.76 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 7.20% | -0.70 | AMGN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.4 | 60.4 | +11.08 | AMGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 1.08 | -0.21 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.0x | 23.0x | +7.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $249.09B | $662.49B | -$413.41B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMGN REV | JNJ REV | AMGN GROSS % | JNJ GROSS % | AMGN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.75B | $94.19B | 67.2% | 67.9% | $8.10B | $19.70B |
| FY 2024 | $33.42B | $88.82B | 61.5% | 69.1% | $10.39B | $19.84B |
| FY 2023 | $28.19B | $85.16B | 44.0% | 44.0% | $7.20B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMGN // BETA 0.87
JNJ // BETA 1.08